Drug profile · INN
idursulfase
ELAPRASE
idursulfase (ELAPRASE) is a heparan sulfate hydrolytic enzyme. Associated with Takeda. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — idursulfase
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- IV (INFUSION)
- Patents
- 0
- Programs
- 10
- Data quality
- 0.89
Quick answer
idursulfase (ELAPRASE) is a heparan sulfate hydrolytic enzyme. Associated with Takeda. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
Heparan sulfate hydrolytic enzyme
Primary target: Heparan sulfate
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is idursulfase?
idursulfase (ELAPRASE) is a heparan sulfate hydrolytic enzyme. Associated with Takeda. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for idursulfase?
ELAPRASE is a marketed brand name for idursulfase. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of idursulfase?
idursulfase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.